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OUTSTANDING among the significant results achieved in recent years in the
study of nucleic acids has been the recognition of the parallelism of their syn-
thesis to mitotic cellular activity (Hershey, 1954; Healy et al., 1956). Owing to
their supreme significance in the metabolism of tumours, and in tumour therapy
efforts are now concentrating on the development and utilization of agents which,
directly or indirectly, act upon them (Skipper and Bennett, 1958 ; Shive and
Skinner, 1958).
Chemotherapeutics, particularly those which act on the nucleic acids, are
nitrogen mustard and its derivatives. One of them is the compound, first
prepared by Vargha (1955) 1, 6-bis (,8-chloroethylamino)-1, 6-dideoxy-D-mannitol-
dihydrochloride, known as Degranol or BCM, the structural formula of which
may be represented as follows
Cl
CH2-NH2-CH2-CH2-ClI I
H-(C-OH
H-C-OH
CH2-NH2-CH2-CH2-CI
Cl-
For its tumour-inhibiting and haematological effects Degranol has been studied
extensively by Kellner and co-workers (Kellner and Nemeth, 1956; Kellner, 1956;
Nemeth, Kellner and Lapis, 1958; Lapis and Nemeth, 1956a, b) who found that
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the morphological changes to which the drug gives rise follow one another at
fairly regular intervals: mitoses begin to be damaged 6 to 12 hours after the
administration of a single dose; the peak effect involving extensive destruction
takes from 48 to 72 hours to appear; and the restitutive stage sets in at about
the 96th hour.
On the analogy of the earlier morphological investigations, we studied the
dynamics ofthe effect Degranol exerts on the nucleic acid metabolism of tumours.
The present paper reports the results of experiments undertaken to shed light
upon the changes which a single dose of the drug brings forth in the incorporation
of 32p into the nucleic acid fractions and acid-soluble nucleotides of transplanted
tumours.
MATERIALS AND METHODS
Experimental animals and their treatment with Degranol.-Inbred albino rats
weighing 120 to 150 g. were inoculated subcutaneously with Guerin carcinoma
and 14 to 16 days later given intravenously a single 50 mg./kg. dose of Degranol.
Following this treatment they were decapitated at various times (24, 48, 72, 96
hours), but always after a 24-hour fast. The tumours they developed were re-
moved and found to weigh from 8 to 12 g. Thin slices were cut offthese tumours,
fixed in formalin and embedded in paraffin for histology. Each tumour was
worked up separately, mostly using its florid parts only. Whole tumours,
however, were used in recovering ribonucleic acid (RNA) according to Pain and
Butler (1957).
The 32p was applied in the form of K2HPO4, after hydrolysis (to eliminate
possible pyrophosphate) and neutralization. Each animal received a 100 ,tc/100
g. intraperitoneal dose of 32p, 24 hours before decapitation.
Specific activity determination of acid-soluble nucleotides.-Hecht and Potter's
(1956) method was employed in extracting the acid-soluble compounds. Tumour
tissue (1 g.) was broken up thoroughly in a Potter-Elvehjem type homogenizer
with 2 ml. of cold 0-6 N perchloric acid. The precipitate was centrifuged and
washed with 0-2 N HC104. The superniatants were pooled and neutralized with
KOH in the presence of phenol red as indicator. The KC104 was centrifuged off
and the tissue inorganic orthophosphate (Pi) was removed by treatment with
magnesia mixture (pH 9) to which unlabelled phosphate had been added.
The acid-soluble nucleotides were then adsorbed from an acid medium on active
carbon and the adsorbate was centrifuged off, washed, and several times eluted
with 50 per cent ethanol containing 2 per cent NH3. The eluate was lyophilized
and the residue taken up in water. Portions of the solution were used for radio-
activity determination and for reading the nucleotide content in a Beckmann
model DU spectrophotometer at 260 m,u in a 1 cm. quartz cuvette. Specific
activity was expressed as cpm/1 E260 11,t, (Pileri and Ledoux, 1957).
Measuring incorporation of 32p into deoxyribonucleic acid (DNA), nuclear RNA
(nRNA) and cytoplasmic RNA (cRNA).-Using a Potter-Elvehjem type homogen-
izer, the fragmented tumour tissue was homogenized in ten times its volume of
cold 0-25 M sucrose containing 0-005 M of CaCl2, and the homogenate was centri-
fuged in the cold at 600 g for 10 minutes, according to the method of Hogeboom,
Schneider and Striebich (1952). Putting aside the cytoplasma supernatant, the
precipitate was twice washed with 0.25 M sucrose, allowed to stand in 2 per cent
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citric acid twice for half ani hour each time, and washed twice with 2 per cent
acetic acid (Nygaard and Rusch, 11955). All washings and centrifugations were
done in the cold; the latter invariably at 600 g for 10 minutes.
The nuclei isolated in the manner described were precipitated with 0 5 N
HC104, and the cytoplasmic fraction was brought to 0 55 N HC104 concentration
(Hurlbert and Potter, 1952). The precipitate was washed in the cold seven
times with 0*2 N HC104 and twice with ethanol, whereafter it was extracted three
times with a 3: 1 mixture of ethanol and ether for 15 minutes at 60° C. The
residue was washed with ether and dried in vacuo. From the drypowderthe nucleic
acids were isolated by the method of Davidson and Smellie (1952): extraction
was performed with 10 per cent NaCl (pH 7) for 60 minutes at 1000 C., and the
procedure was repeated. The cRNA and nRNA were hydrolyzed with 0 3 N
KOH for 16 hours at 300 C. In the nuclear fraction the DNA was separated from
the RNA nucleotides by acidification following hydrolysis. The DNA was
immediately centrifuged off, dissolved in dilute NH40H, purified by repeated
precipitation, and finally dissolved in dilute NH40H.
Possible contaminating Pi was removed from the RNA nucleotides by means
of magnesia mixture with unlabelled Pi added to it.
Portions ofRNA and DNA fractions were used for radioactivity determinations
and for reading the nucleic acid contents. The RNA content was determined
by Mejbaum's (1939) orcinol reaction as modified by Ceriotti (1955), and the
colour was read at 660 m,t on the Beckmann model DU spectrophotometer. The
DNA content was determined by Dische's (1930) diphenylamine reaction as
modified by Seibert (1940) and the colour was read at 600 m,u on the Beckmann
model DU spectrophotometer. Specific activity was expressed as cpm/100 ,ug.
of RNA-P and DNA-P, respectively.
Relative specific activity.-Following Smellie et al. (1955), the specific activity
of the nucleotides and nucleic acids was referred to that of the Pi in the blood of
the experimental animal and stated as relative specific activity, i.e.
specific activity of fraction studied Relative specific activity X 10000 spec&fkc atvyofblWood Pi
Determination of specific activity of Pi in the blood.-The decapitated animal's
blood was collected, and half its volume of trichloroacetic acid (20 per cent) was
added to it. The mixture was centrifuged, and from the supernatant the Pi was
isolated in the cold with magnesium mixture (pH = 9) as MgNH4PO4. This was
recrystallized, and dissolved in dilute acid. Portions of the solution were then
used to determine Pi by the method of Fiske and Subbarow (1925), as modified by
Lohmann and Jendrassik (1926) and to measure radioactivity. Specific activity
was expressed as cpm/100 ,ag. ofPi; as mentioned above, to this was referred the
specific activity of the nucleotides and nucleic acids, respectively, to be stated as
the relative specific activity.
Isolation of RNA for heterogeneity tests was performed by the method of
Pain and Butler (1957). The specific activity of the RNA so obtained was ex-
pressed as cpm/100 ,ug. of ribose.
Radiation count.-Portion of the solution to be studied was measured into an
aluminium dish and there allowed to dry. Radioactivity was then measured
under an end-window GM tube, with the aid of an Orion 1871 type counter.
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RESULTS
Earlier animal experiments (Antoni et al., 1958; Antoni, Vargha and Hidvegi,
1959) showed that for the isolation of RNA from liver labelled with 32p in vivo,
a 24-hour circulation time was the ideal. Even with subcellular particles this
circulation time proved to be the best for labelling nucleic acids. Support for
these findings has been provided by the work of Tyner, Heidelberger and LePage,
(1953) on tumours, for which, in turn, we have established confirmation in respect
of Guerin tumour.
TABLE I.-Effect of Degranol on Relative Specific Activity
of Tumour Nucleic Acids
100 Hc of 32P/100 g. of body weight injected 24 hours before decapitation.
The figures in brackets indicate the number of animals involved
Relative specific activity
Duration of , -
treatment DNA nRNA cRNA
Control . . 3,950 (9) 10,650 (10) 8,300 (10)
3,530-4,200 9,150-11,020 6,950-8,750
24 hours 1,850 (3) 7.530 (3) 8,050 (3)
1,410-2,460 7,100-9,820 7,050-8,250
48 hours 1,520 (4) 6,810 (4) 7,250 (4)
1,120-1,860 6,170-7,830 6,810-7 750
72 hours . 920 (7) 4,950 (7) 4,220 (7)
Experiment a 720-1,040 4,610-6,050 3,790-4,540
72 hours . 2,900 (3) 10,920 (3) 9,210 (3)
Experiment b 1,940-3,720 9,100-11,430 7,110-9,850
96 hours . . . 4,420 (3) 11,250 (3) 8,820 (3)
3,840-4,960 10,620-12,700 8 070-9,440
Table I illustrates the effect Degranol exerted in our experiments on the
incorporation of 32p into tumoural nucleic acids. It shows that the drug caused
their relative specific activity to decline at rates which followed a certain chrono-
logical regularity. The decrease was most marked in DNA: more than 50 per
cent in 24 hours and reaching its minimum in 72 hours. It was less marked in
nRNA and cRNA. At 96 hours after Degranol, i.e. at the time corresponding
to the beginning of the restitutive stage as established by morphology, the
relative specific activity of all the three nucleic acids studied was found to have
returned to the level seen in the controls. In some cases, as early as 72 hours
after treatment the relative specific activity was of the same order of magnitude
in the experimental as in the control animals (cf. 72-hour experiment b in
Table I). Histological examination showed the tumours of these animals to be
in the restitutive stage.
Since in the current view the acid-soluble nucleotides are possible precursors
of the nucleic acids our investigations were extended to the changes in their
relative specific activity which follow treatment with Degranol. Table II
illustrates the effect the drug had on the relative specific activity of acid-soluble
nucleotides isolated simultaneously with nucleic acids and purified on active
carbon. The data reveal that similar dynamic forces were at work in shaping
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the relative specific activity of both sources: the purified acid soluble nucleotides
and the nucleic acids. In some of our experiments the number of counts,
registered 72 hours after Degranol, was found closely to approach the limit of
errors; when averaging experimental results such counts were taken into con-
sideration as non-radioactive values only.
TABLE II.-Effect of Degranol on Relative Specific Activity of
Acid-soluble Tumour Nucleotides
100 tjC of 32P/100 g. of body weight injected 24 hours before decapitation.
The figures in brackets inicate the number of animals involved
Duration of Relative specific
treatment activity
Control . . 310 (10)
262-340
24 hours . . . 150 (3)
120-194
48 hours . . . 82 (4)
47-113
72 hours . 20 (7)
Experiment a 0-73
72 hours . . . 194 (3)
Experiment b 153-260
96 hours . . . 320 (3)
290-365
It was possible for us to verify our results in RNA fractions isolated by a
different route (Pain and Butler, 1957).
The RNA was isolated from whole tumours, its specific activity was deter-
mined, and its heterogeneity studied (Antoni, Hidvegi and Lapis, 1960).
In Table III our experimental results are presented so as to demonstrate the
decrease in the rate of 32p incorporation following treatment with Degranol;
in other words, the specific activity of the RNA in the tumour of the treated
TABLE III.-Incorporation of 32p into RNA Isolatedfrom
Whole Tumour According to Pain and Butler (1957)
100 ,tc of 32P/100 g. of body weight injected 24 hours before decapitation
Duration of Specific activity = control cpm/100 ,ug. of ribose
treatment treated cpm/100 ,ug. of ribose
24 hours . . 1-86 (3)
1-30-2-15
72 hours . . 2-77 (6)
2-27-4-16
96 hours . . 1-81 (3)
1-50-2-16
animal is referred to that in the tumour of the corresponding control animal.
These data show that alterations induced by the drug in the rate ofincorporation
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of 32p follow the same trend in RNA isolated by a different method, namely,
from whole tumour.
DISCUSSION
Bodenstein (1947) was the first to study the effect ofnitrogen mustard onnucleic
acid metabolism. He found that the compound inhibited DNA synthesis, but
assumed it had no inhibitory effect on the synthesis of RNA. (It would
appear that the drug has no such effect on nuclei during mitosis, but does exert
it in the interphase following mitosis.) Several authors hold similar views
(Lowrance and Carter, 1950; Skipper et al., 1951; Goldthwait, 1952). Harold
and Zipporin recently found that mustard derivatives induced a transient inhibi-
tion of DNA synthesis in Escherichia coli, but allowed RNA and protein synthesis
to continue unchanged.
Not unlike that of the other mustard derivatives, the initial effect of Degranol
(between 6 and 24 hours) is to damage mitoses and bringdownthe total number of
cell divisions. The peak effect falls between 48 and 72 hours, manifesting itself
in extensive cellular and nuclear disintegration in the florid parts of the tumour,
considerable expansion of necrotic areas, and the appearance of anomalous
mitoses (cacomitoses) and multinuclear tumour changes are followed by the
restitutive phase characterized by a cell population consisting predominantly of
giant cells (Kellner and Nemeth, 1956; Kellner, 1956; Nemeth, Kellner and
Lapis, 1958; Lapis and Nemeth, 1956a, 1956b).
On the evidence ofour experimental results treatment with Degranol is followed
by a decrease in the incorporation of 32p into the nucleic acids and acid-soluble
nucleotides of Guerin tumour. At the time it exerts its maximum effect the drug
reduces the level of incorporation into DNA to about a quarter of the original.
Incorporation into RNA and cRNA likewise shows decreases; these however
are less marked.
Our results, further, permit the statement that the changes in nucleic acid
metabolism seen after Degranol are a dynamic process, the same as the morpho-
logical changes. In 24 hours a single dose decreases the relative specific activity
of DNA by 50 per cent and reduces the total number of cell divisions. The drug
exerts its maximum effect between the 48th and 72nd hour after input. This is the
time when the morphological picture shows extensive cellular and nuclear disinte-
gration and a progressive decline to the minimum of the relative specific activity
of the nucleic acid fractions. This gradual decrease is particularly marked in
DNA, a phenomenon which fairly corresponds to the extensive nuclear disintegra-
tion revealed by morphology. Conformity with the morphological picture is
still more pronouned at 96 hours, when the relative specific activity of DNA,
nRNA, and cRNA is observed to have returned to the level seen in the controls,
coinciding with the appearance ofmultinuclear giant cells and amitoses in numbers
so great as to be practically the only building stones of the entire florid tumours.
Conflicting interpretations of these cell forms are offered in the literature.
Many authors have brought them into connection with regressive processes. The
view, however, is gaining ever more adherents that they are very frequent and
interesting forms of cell division. Kellner's studies (1952, 1960) also favour the
idea that these kinds ofcells have a decisive part to play in the restitutive processes
that follow damages caused by chemotherapeutics. By our findings, at the time
these cells come into prominence the level ofrelative specific activity ofDNA rises
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to that observed in the controls, which phenomenon seems to confirm that their
appearance may actually be connected with processes progressive, and not
regressive.
While in some cases, at 72 hours after Degranol the relative specific activity
was the same in the experimental animals as in the controls, in others it showedthe
low level which characterized the maximal effect of the drug. Such differences,
however, were invariably found to conform with the changes established by
morphology. For, whenever the relative specific activity was as high as in the
controls, the histological picture revealed changes typical of the restitutive stage;
conversely, whenever it was low, histology still showed marked nuclear destruc-
tion.
It seems safe to claim that our results offer the possibility of quantitatively
characterizing the alterations and their individual phases, to which the mustard
derivatives give rise in the tumour-and which hitherto couldonly be differentiated
qualitatively on the strength of morphological changes-by measuring the incor-
poration of 32p into the nucleic acids.
SUMINIARY
The compound 1, 6-bis-(,8-chloroethylamino)-1, 6-dideoxy-D-mannitol-dihydro-
chloride (Degranol; BCM) has been studied for its effects on the nucleic acid
metabolism of Guerin carcinoma transplanted into rats. A single dose of the
drug was found to decrease incorporation of 32p into the various nucleic acid
fractions. At 72 hours after injection the decrease was most marked in DNA.
It was less marked in nRNA and cRNA. At 96 hours, 32p incorporation into all
the three nucleic acids studied was seen to have returned to the levels observed
in the control animals. Variations of a similar trend were noted in the acid-
soluble nucleotide fractions isolated simultaneously with the nucleic acids.
The conclusion is drawn that the changes occurring in the nucleic metabolism
of tumours represent a dynamic process, as do the morphological changes.
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